Purdue University — Imatinib Trial for Drug-Resistant Malaria

[Human Health and Wellbeing] Open Philanthropy recommended a grant of $600,000 over three years to Purdue University to support a phase III trial of imatinib, a drug previously approved to treat leukemia, to test its efficacy against drug-resistant strains of malaria in Vietnam. This research will be coordinated by Professor Philip Low, who previously organized a successful phase II trial of imatinib. This falls within our focus area of scientific research, specifically within our interest in advancing human health and wellbeing.